157 related articles for article (PubMed ID: 37132470)
1. A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial.
Schultheis M; Staubach P; Nikolakis G; Schollenberger L; Mauch M; Burckhardt M; Heise M; Zamsheva M; Strobel A; Langer G; Bechara F; Kirschner U; Hennig K; Kunte C; Goebeler M; Grabbe S
Br J Dermatol; 2023 Jul; 189(2):170-179. PubMed ID: 37132470
[TBL] [Abstract][Full Text] [Related]
2. A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effectiveness.
Heise M; Staubach P; Nikolakis G; Schollenberger L; Mauch M; Burckhardt M; Zamsheva M; Strobel A; Langer G; Bechara F; Kirschner U; Hennig K; Kunte C; Goebeler M; Podda M; Grabbe S; Schultheis M
J Dermatolog Treat; 2023 Dec; 34(1):2284105. PubMed ID: 38010850
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
[TBL] [Abstract][Full Text] [Related]
4. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
5. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial.
Schultheis M; Staubach P; Nikolakis G; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC
Dermatology; 2022; 238(3):476-486. PubMed ID: 34535610
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
7. Automatic International Hidradenitis Suppurativa Severity Score System (AIHS4): A novel tool to assess the severity of hidradenitis suppurativa using artificial intelligence.
Hernández Montilla I; Medela A; Mac Carthy T; Aguilar A; Gómez Tejerina P; Vilas Sueiro A; González Pérez AM; Vergara de la Campa L; Luna Bastante L; García Castro R; Alfageme Roldán F
Skin Res Technol; 2023 Jun; 29(6):e13357. PubMed ID: 37357665
[TBL] [Abstract][Full Text] [Related]
8. The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis.
Montero-Vilchez T; Diaz-Calvillo P; Rodriguez-Pozo JA; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34206415
[TBL] [Abstract][Full Text] [Related]
9. Clindamycin-Benzoyl Peroxide Gel Compared with Clindamycin Lotion for Hidradenitis Suppurativa: A Randomized Controlled Assessor-Blinded Intra-Patient Pilot Study.
Aarts P; Reeves JL; Ardon CB; van der Zee HH; Prens EP
Dermatology; 2023; 239(4):670-674. PubMed ID: 37080176
[TBL] [Abstract][Full Text] [Related]
10. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
[TBL] [Abstract][Full Text] [Related]
11. Long-Wave Medical Infrared Thermography: A Clinical Biomarker of Inflammation in Hidradenitis Suppurativa/Acne Inversa.
Zouboulis CC; Nogueira da Costa A; Jemec GBE; Trebing D
Dermatology; 2019; 235(2):144-149. PubMed ID: 30650424
[TBL] [Abstract][Full Text] [Related]
12. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.
Daoud M; Suppa M; Benhadou F; Daxhelet M; Njimi H; White J; Jemec G; Del Marmol V
Front Med (Lausanne); 2023; 10():1145152. PubMed ID: 37138732
[TBL] [Abstract][Full Text] [Related]
13. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
14. Assessing the psychological burden of patients with hidradenitis suppurativa.
Frings VG; Bauer B; Glöditzsch M; Goebeler M; Presser D
Eur J Dermatol; 2019 Jun; 29(3):294-301. PubMed ID: 31145081
[TBL] [Abstract][Full Text] [Related]
15. Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
Włodarek K; Stefaniak A; Matusiak Ł; Szepietowski JC
Dermatology; 2020; 236(1):8-14. PubMed ID: 31487719
[TBL] [Abstract][Full Text] [Related]
16. Drivers of disease severity and burden of hidradenitis suppurativa: a cross-sectional analysis on 553 German patients.
Schultheis M; Grabbe S; Staubach P; Hennig K; Mauch M; Burckhardt M; Langer G; Heise M; Zamsheva M; Schollenberger L; Strobel A
Int J Dermatol; 2024 Feb; 63(2):188-195. PubMed ID: 37919257
[TBL] [Abstract][Full Text] [Related]
17. Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.
Prens EP; Lugo-Somolinos AM; Paller AS; Kerdel F; Duan Y; Teixeira HD; Longcore M; Kimball AB
Am J Clin Dermatol; 2020 Aug; 21(4):579-590. PubMed ID: 32077014
[TBL] [Abstract][Full Text] [Related]
18. A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.
Jepsen R; Edwards C; Flora A; Kozera E; Frew JW
J Am Acad Dermatol; 2023 Oct; 89(4):694-702. PubMed ID: 37307994
[TBL] [Abstract][Full Text] [Related]
19. Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease.
Fabbrocini G; Ruina G; Giovanardi G; Dini V; Raone B; Venturini M; Caposiena Caro RD; Veraldi S; Cannavò SP; Merlo G; Bertoldi AM; Fiorentini F; Molinelli E; Atzori L; Bongiorno MR; Lo Re M; Skroza N; Lasagni C; Franchi C; Ardigò M; Di Costanzo L; Stingeni L; Amerio P; Sanna F; Pescitelli L; Broganelli P; De Cupis C; Gualberti G; Saragaglia V; Argenziano G
Dermatology; 2022; 238(3):487-497. PubMed ID: 34474409
[TBL] [Abstract][Full Text] [Related]
20. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.
Ingram JR; Bettoli V; Espy JI; Kokolakis G; Martorell A; Villani AP; Wallinger H; Coak E; Kasparek T; Muscianisi E; Richardson C; Kimball AB
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1597-1605. PubMed ID: 35445469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
